Screening of new antifungal compounds in a collection of chemical products

Journal de Mycologie Medicale

Volumn 13, Issue 4, 2003, Pages 189-192

  Lemriss, S ^a,b   Marquet, B ^a   Ginestet, H ^a   Lefeuvre, L ^a   Fassouane, A ^b   Boiron, P ^a  

^a UNIVERSITÉ LYON 1   (France)

^b FACULTÉ DES SCIENCES   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMPHOTERICIN B; ANTIFUNGAL AGENT; NYSTATIN;

AGAR GEL DIFFUSION; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CANDIDA ALBICANS; CANDIDA TROPICALIS; CELL DENSITY; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG SCREENING; FUNGUS GROWTH; FUSARIUM OXYSPORUM; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; STRAIN DIFFERENCE; TRICHOPHYTON RUBRUM;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CANDIDA; CANDIDA ALBICANS; CANDIDA TROPICALIS; FUNGI; FUSARIUM; FUSARIUM OXYSPORUM; TRICHOPHYTON; TRICHOPHYTON RUBRUM;

EID: 0742270905     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Dannaoui E, Lortholary O, Dromer F. Technique des associations d'antifongiques in vitro et in vivo chez l'animal. J Mycol Med 2003;13:73-85.
2. Thiebaut A. Empirical treatment by antifungal drugs in febrile neutropenia. J Mycol Med 2002;12:115-9.
3. Lortholary O, Denning WD, Dupont B. Endemic mycoses: a treatment update. J Antimicrob Chemother 1999;43:321-31.
4. Andriole VT. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 1999;44:151-62.
5. Dupont B. Choix et emploi des médicaments antifongiques. Rev Prat 2001;51:1-6.
6. Datry A, Thellier M. Les échinocandines: une nouvelle classe thérapeutique antifongique, un nouveau mécanisme d'action. J Mycol Med 2002;12:1S5-1S9.
7. Imbert C, Imbert S, Rodier MH, Jacquemin JL. Effet des concentrations sub-inhibitrices d'antifongiques systémiques sur les capacités d'adhérence et de filamentation et sur le métabolisme mitochondrial de Candida albicans. J Mycol Med 2001;11:14-8.
8. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24:235-47.
9. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Sentry participants group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazoles and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002;46:1032-7.
10. Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ. In vitro activities of 5-fluorocytosine against 8803 clinical isolates of Candida spp.: global assessement of primary resistance using national committee for clinical laboratory standards susceptibility testing methods. Antimicrob Agents Chemother 2002;46:3518-21.
11. Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and others pathogenic yeasts. Antimicrob Agents Chemother 1998;42:1057-61.